Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Masitinib alone or with dacarbazine in unresectable or metastatic melanoma
2010-018982-43Phase 2Completed
- Sponsor
- AB Science
- Start
- Feb 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of masitinib and dacarbazine in melanoma (2 arms), sponsored by AB Science. Primary endpoints: Safety and tolerability and Efficacy. Started Feb 2010; status: completed.
02
Drugs
masitinibdacarbazine
03
Conditions
melanoma
Beyond the preview
Go deeper on 2010-018982-43.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018982-43.